Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report

Peter G Rose1

  • 1Section of Gynecologic Oncology, Women's Health Institute, Cleveland Clinic, A-81, 9500 Euclid Ave., Cleveland, OH 44195, USA.

PubMed